GRP and breast cancer: In vivo, in the athymic mice breast cancer xenograft model, [177Lu]Lu-DenAuNP-folate-bombesin presented satisfactory radioactivity retention up to 96 h after intratumoral injection and allowed high-quality optical imaging.